Research programme: apoptotic DNA immunotherapy - type 1 diabetes mellitus - Sekris Biomedical

Drug Profile

Research programme: apoptotic DNA immunotherapy - type 1 diabetes mellitus - Sekris Biomedical

Alternative Names: SKRS 95

Latest Information Update: 23 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SEKRIS Biomedical
  • Class Diabetes mellitus vaccines; DNA vaccines
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 22 Feb 2016 Preclinical trials in Type-1 diabetes mellitus in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top